Inspectors cite Calder Vale Peptides of Skipton over sterility assurance

Inspectors have cited Calder Vale Peptides of Skipton over sterility assurance at its sterile-preparation suite, according to an inspection report reviewed by the Journal. The observations include an inadequate media-fill programme, environmental monitoring excursions closed without investigation, and a quality unit whose reporting line ran to the production manager rather than independently.

The observations, in the order the report lists them: media fills not performed at the required frequency; smoke studies not repeated after a change to the airflow configuration; 21 environmental monitoring excursions closed without a documented investigation; personnel gowning qualification records incomplete for two operators; and a quality unit lacking independent authority to reject a batch.

The letter records that the firm was given 15 days to respond to the initial observations and did so, that the response was found inadequate in respect of 21 of the observations, and that the specific inadequacy was a corrective action plan without a root-cause analysis. That sequence — observation, response, response found inadequate, letter — is the ordinary path and takes months.

Enforcement in this sector is slow by design: inspection, observation, response, escalation, letter, and only then injunction or decree. The consequence is that a facility with a serious quality problem can continue operating for a year or more while the process runs, and that the closure, when it comes, appears sudden to everyone outside it.

"A batch range instead of a lot list is a decision," said Dr Farida Al-Mansouri, internal medicine physician, Doha. "It is cheaper for the company and it transfers the work to every pharmacist holding stock."

"A batch range instead of a lot list is a decision," said Dr Tomás Iriarte, endocrinologist, Hospital Italiano de Buenos Aires. "It is cheaper for the company and it transfers the work to every pharmacist holding stock."

The Journal has asked Calder Vale Peptides of Skipton for comment and will publish any response in full. The company’s earlier statement said it was cooperating with the regulator and had no further comment.